A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26

Yu, Miao; Chi, Xiaosa; Huang, Shunlin; Wang, Zhiping; Chen, Jie; Qian, Ciying; Han, Feng; Chen, Lin; Li, Jinjin; Sun, Hui; Zhou, Lizhi; Li, Tingting; Wang, Yingbin; Zheng, Qingbing; Yu, Hai; Zhang, Jun; Xia, Ningshao; Li, Shaowei; Gu, Ying

doi:10.1016/j.vaccine.2022.09.010

Cited by 5 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been extensively investigated to produce chimeric vaccines against evolving pathogens. E. coli -expressed chimeric multivalent (triple-type) vaccines against human papillomavirus (HPV) have been well characterized and resulted in promising translatability and qualities [ 64 , 65 ]. Middelberg et al [ 66 ] utilized E. coli host as an effective platform to produce prophylactic chimeric VLPs based on murine polyomavirus VP1 capsomeres.…”

Section: Expression Platforms and Upstream Process Development Of Chi...mentioning

confidence: 99%

Challenges and Opportunities in the Process Development of Chimeric Vaccines

Chauhan,

Khasa

2023

Vaccines

View full text Add to dashboard Cite

Vaccines are integral to human life to protect them from life-threatening diseases. However, conventional vaccines often suffer limitations like inefficiency, safety concerns, unavailability for non-culturable microbes, and genetic variability among pathogens. Chimeric vaccines combine multiple antigen-encoding genes of similar or different microbial strains to protect against hyper-evolving drug-resistant pathogens. The outbreaks of dreadful diseases have led researchers to develop economical chimeric vaccines that can cater to a large population in a shorter time. The process development begins with computationally aided omics-based approaches to design chimeric vaccines. Furthermore, developing these vaccines requires optimizing upstream and downstream processes for mass production at an industrial scale. Owing to the complex structures and complicated bioprocessing of evolving pathogens, various high-throughput process technologies have come up with added advantages. Recent advancements in high-throughput tools, process analytical technology (PAT), quality-by-design (QbD), design of experiments (DoE), modeling and simulations, single-use technology, and integrated continuous bioprocessing have made scalable production more convenient and economical. The paradigm shift to innovative strategies requires significant attention to deal with major health threats at the global scale. This review outlines the challenges and emerging avenues in the bioprocess development of chimeric vaccines.

show abstract

Section: Expression Platforms and Upstream Process Development Of Chi...mentioning

confidence: 99%

Challenges and Opportunities in the Process Development of Chimeric Vaccines

Chauhan,

Khasa

2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…The triple-type chimera of HPV33/58/52 VLPs induced neutralization titers comparable to a mixture of the three wild-type VLPs in mice and non-human primates (Li et al, 2018). The authors are currently developing seven type-cross vaccines against 20 HPV variants based on this strategy (Qian et al, 2022;Yu et al, 2022). A plant-based VLPs vaccine against COVID-19 developed by Medicago Inc. was recently authorized for use in Canada (Ward et al, 2021).…”

Section: Virus-like Particle and Nanoparticle Vaccinesmentioning

confidence: 99%

Current progress in the development of prophylactic and therapeutic vaccines

Qian

et al. 2022

Sci. China Life Sci.

Self Cite

View full text Add to dashboard Cite

Vaccines are essential public health tools and play an important role in reducing the burden of infectious diseases in the population. Emerging infectious diseases and outbreaks pose new challenges for vaccine development, requiring the rapid design and production of safe and effective vaccines against diseases with limited resources. Here, we focus on the development of vaccines in broad fields ranging from conventional prophylactic vaccines against infectious diseases to therapeutic vaccines against chronic diseases and cancer providing a comprehensive overview of recent advances in eight different vaccine forms (live attenuated vaccines, inactivated vaccines, polysaccharide and polysaccharide conjugate vaccines, recombinant subunit vaccines, virus-like particle and nanoparticle vaccines, polypeptide vaccines, DNA vaccines, and mRNA vaccines) and the therapeutic vaccines against five solid tumors (lung cancer breast cancer colorectal cancer liver cancer and gastric cancer), three infectious diseases (human immunodeficiency virus, hepatitis B virus and human papillomavirus-induced diseases) and three common chronic diseases (hypertension, diabetes mellitus and dyslipidemia). We aim to provide new insights into vaccine technologies, platforms, applications and understanding of potential next-generation preventive and therapeutic vaccine technologies paving the way for the vaccines design in the future.

show abstract